Navigation Links
GENova names Aaron Whiteman as CEO
Date:8/18/2009

NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

Mr. Whiteman, is a graduate of Oxford University and London School of Economics. He will provide GENova with his unique blend of exceptional sales, marketing, business and networking skills, combined with solid business management experience and the vision to marry novel products with new market opportunities. Mr. Whiteman has extensive experience in team building and negotiation. He has previously worked with companies such as Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and Biogen Idec (Nasdaq: BIIB).

Mr. Whiteman said, "I am excited to provide the executive leadership to take GENova to its next stage of growth in this crucial phase of commercializing GENova's technology in the marketplace."

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers and infectious disease. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.At present, GENova is rapidly building its portfolio of proprietary biotechnology. GENova's target market - cancer treatments - is the largest disease market, exploding at a 20% growth rate each year. GENova's treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). GENova has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , ... first national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast ... Quack Gives Back initiative, and we’re very pleased with the participation in ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Texas , Dec. 9, 2016  RxWiki Inc., ... apps, and digital marketing strategies of thousands of pharmacies ... it won Austin Inno,s "50 on Fire" ... "We,re pleased to accept the award as ... Loughlin , Chief Executive Officer at RxWiki. "Our platform ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
Breaking Medicine Technology: